NICE rejects Erbitux again
This article was originally published in Scrip
Executive Summary
Health technology assessors for England and Wales are preparing to reject Merck Serono's (Merck KGaA) Erbitux (cetuximab) in yet another indication: recurrent and/or metastatic squamous cell carcinoma of the head and neck.